



66

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/645,250		
		Filing Date	August 20, 2003		
		First Named Inventor	Mahajan et al.		
		Art Unit	1636		
		Examiner Name	Ramnar Acharya / Guy Guidry		
Sheet	1	of	5	Attorney Docket Number	57953/1151

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patent or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
GG	1	US-4,788,222	11-29-1988	Rice et al.	
GG	2	US-6,335,194	1-2-2002	Bennett et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patent or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ² Number ² Kind Code ² (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
GG	3	ANZICK et al., "AIB1, A Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer," <i>Science</i> 277:965-968 (1997)	
GG	4	ARANDA et al., "Nuclear Hormone Receptors and Gene Expression," <i>Physiol. Rev.</i> 81:1269-1304 (2001)	
GG	5	ARAVIND, "The BED Finger, A Novel DNA-Binding Domain in Chromatin-Boundary-Element-Binding Proteins and Transposases," <i>Trends Biochem. Sci.</i> 25:421-423 (2000)	
GG	6	BLANCO et al., "The Histone Acetylase PCAF is a Nuclear Receptor Coactivator," <i>Genes Dev.</i> 12:1638-1651 (1998)	
GG	7	CAIRA et al., "Cloning and Characterization of RAP250, A Novel Nuclear Receptor Coactivator," <i>J. Biol. Chem.</i> 275:5308-5317 (2000)	
GG	8	CHAKRAVARTI et al., "Role of CBP/P300 in Nuclear Receptor Signalling," <i>Nature</i> 383:99-103 (1996)	
GG	9	CHEN et al., "Regulation of Transcription by a Protein Methyltransferase," <i>Science</i> 284:2174-2177 (1999)	

Examiner Signature	/Guy Guidry/ (05/26/2006)	Date Considered	05/26/2006
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.